| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1111499033 |
| P356 | DOI | 10.1038/S41398-018-0353-X |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/s41398-018-0353-x |
| P932 | PMC publication ID | 6336814 |
| P698 | PubMed publication ID | 30655505 |
| P50 | author | Natalie Musial | Q61473363 |
| Roger S McIntyre | Q88039086 | ||
| Elisa Brietzke | Q89614022 | ||
| P2093 | author name string | Jing Zeng | |
| Ninghua Huang | |||
| Bing Cao | |||
| Jingyu Wang | |||
| Dongfang Wang | |||
| Rodrigo B Mansur | |||
| Zihang Pan | |||
| Mehala Subramanieapillai | |||
| P2860 | cites work | A systematic review of the prevalence of schizophrenia | Q21144720 |
| Common variants on chromosome 6p22.1 are associated with schizophrenia | Q24641881 | ||
| Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? | Q24813193 | ||
| Acylcarnitines: reflecting or inflicting insulin resistance? | Q27004603 | ||
| Fatty acid import into mitochondria | Q28138465 | ||
| A review of current evidence for acetyl-l-carnitine in the treatment of depression | Q28235560 | ||
| Cardiovascular Risk Factors Associated With Blood Metabolite Concentrations and Their Alterations During a 4-Year Period in a Population-Based Cohort | Q30313790 | ||
| Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder | Q30534798 | ||
| Interactions of acyl carnitines with model membranes: a (13)C-NMR study | Q30724131 | ||
| Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice | Q34253068 | ||
| Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns | Q34272296 | ||
| Carnitine: a nutritional, biosynthetic, and functional perspective | Q34347813 | ||
| Carnitine biosynthesis in mammals | Q34501779 | ||
| Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study | Q34622940 | ||
| Acylcarnitines: potential implications for skeletal muscle insulin resistance | Q34847808 | ||
| A mitochondrial carnitine acylcarnitine translocase system | Q35072156 | ||
| Carnitine metabolism and deficit--when supplementation is necessary? | Q35137778 | ||
| Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? | Q35768175 | ||
| Role of carnitine esters in brain neuropathology | Q35885447 | ||
| In situ assay of fatty acid β-oxidation by metabolite profiling following permeabilization of cell membranes | Q35896995 | ||
| Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. | Q51474477 | ||
| Neurocognitive and social functioning in schizophrenia. | Q51986093 | ||
| Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study. | Q52996147 | ||
| L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. | Q53180946 | ||
| Differentiating Medicated Patients Suffering from Major Depressive Disorder from Healthy Controls by Spot Urine Measurement of Monoamines and Steroid Hormones. | Q55032429 | ||
| Carnitine biosynthesis in mammals | Q56094872 | ||
| Quantitative analysis of plasma acylcarnitines using gas chromatography chemical ionization mass fragmentography | Q73075492 | ||
| A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis | Q83142197 | ||
| Lipid-induced mitochondrial stress and insulin action in muscle | Q35947486 | ||
| Identification and validation of urinary metabolite biomarkers for major depressive disorder | Q36508139 | ||
| Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control | Q37371666 | ||
| Carnitine in the treatment of valproic acid-induced toxicity | Q37413086 | ||
| Acylcarnitines: role in brain. | Q37589801 | ||
| Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis | Q37648311 | ||
| Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. | Q37680618 | ||
| Prevalence of obesity and diabetes in patients with schizophrenia | Q38598772 | ||
| Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. | Q38743021 | ||
| Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study | Q38879830 | ||
| Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial | Q38918313 | ||
| Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis | Q38981510 | ||
| Altered reward anticipation: Potential explanation for weight gain in schizophrenia? | Q39112351 | ||
| Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance | Q40028148 | ||
| Changes in the human plasma and urinary metabolome associated with acute dietary exposure to sucrose and the identification of potential biomarkers of sucrose intake | Q40537286 | ||
| Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study | Q40662987 | ||
| Low levels of short- and medium-chain acylcarnitines in HIV-infected patients | Q40778270 | ||
| Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine | Q40865200 | ||
| Acylcarnitines profile best predicts survival in horses with atypical myopathy | Q41532686 | ||
| Carnitine transport and fatty acid oxidation | Q41633875 | ||
| Short- and medium-chain fatty acids in energy metabolism: the cellular perspective | Q42766173 | ||
| Liver L-carnitine biosynthesis in non-pregnant, pregnant and lactating rabbits | Q44970943 | ||
| Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry | Q45263649 | ||
| Acylcarnitine profile in thyroid disease. | Q46298876 | ||
| Long-chain acylcarnitines determine ischaemia/reperfusion-induced damage in heart mitochondria. | Q46586193 | ||
| Neuroimaging-aided differential diagnosis of the depressive state | Q46918626 | ||
| Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment | Q48275162 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 19 | |
| P577 | publication date | 2019-01-17 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study | |
| P478 | volume | 9 |
| Q102053746 | Key role for lipids in cognitive symptoms of schizophrenia |
| Q97066895 | Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques |
Search more.